Tag Archives: Adynovi

March, 2016

  • 2 March

    Baxalta Submits MAA to the EMA for its Hemophilia A Treatment

    BANNOCKBURN, Ill.–(BUSINESS WIRE)– Baxalta Incorporated (NYSE:BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval of ADYNOVI, an extended circulating half-life recombinant Factor …